Alessandro Sette

Alessandro Sette is an Italian immunologist. He was born on August 11, 1960, in Rome, Italy, to Pietro Sette, a prominent Italian businessman and politician, and Renata Sette. Sette is a professor at the La Jolla Institute for Immunology (LJI). He is an adjunct professor at the University of California, San Diego. Sette studies the specific epitopes that the immune system recognizes in cancer, autoimmunity, allergy, and infectious diseases.

In 1988, Sette moved to San Diego to conduct research at San Diego biotech Cytel. He then co-founded Epimmune. In 2003, Sette joined the faculty of the La Jolla Institute for Immunology.

Sette co-leads the Immune Epitope Database (IEDB), an NIAID-funded online database that catalogues epitopes involved in immune system recognition of allergens, infectious diseases, autoantigens, and transplanted tissue in humans and various species.

In 2020, Sette published the first study of SARS-CoV-2 epitopes targeted by the human immune system. He has co-led research into CD8+ and CD4+ T cell responses in COVID-19 patients and studied CD8+ T cell cross-reactivity to SARS-CoV-2 epitopes and other coronaviruses.

Throughout his career, Sette has maintained strong scientific ties with Italy and currently is a [https://www.issnaf.org/leadership Member of the Scientific Council of ISSNAF], a not-for-profit organization whose mission is to connect, empower and celebrate the Italian Intellectual Diaspora in North America. He was recently named as a [https://www.issnaf.org/leadership Member of] [https://www.issnaf.org/leadership ISNAFF's Board of Directors]. In 2025, Sette was awarded the title of "[https://www.issnaf.org/post/prof-alessandro-sette-awarded-italy-s-highest-civilian-honor-cavaliere-dell-ordine-al-merito-della Cavaliere dell'Ordine al Merito della Repubblica Italiana]" in recognition of his contributions to biomedical science and global health. Provided by Wikipedia